Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series.

Autor: Kam CW; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA., McKinzie CJ; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA., Omecene NE; Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA., Peters S; College of Pharmacy and Allied Health Professions, South Dakota State University, Brookings, South Dakota, USA., Pettit RS; Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana, USA., Poisson MO; Department of Pharmacy, Children's Hospital of Georgia, Augusta, Georgia, USA., Witte J; Department of Pharmacy, Driscoll Children's Hospital, Corpus Christi, Texas, USA.
Jazyk: angličtina
Zdroj: Pediatric pulmonology [Pediatr Pulmonol] 2024 Dec 20, pp. e27455. Date of Electronic Publication: 2024 Dec 20.
DOI: 10.1002/ppul.27455
Abstrakt: Following the approval of elexacaftor/tezacaftor/ivacaftor (ETI), there have been post-marketing reports and published cases of papilledema and intracranial hypertension in children with cystic fibrosis (CF) taking ETI. In those reports, the patients often presented with marked symptoms and concomitant hypervitaminosis A. In this multicenter case series, we report eight cases of papilledema in children with CF taking ETI that were diagnosed via routine eye exam, the majority of whom presented with minimal to no symptoms and all had normal serum Vitamin A levels.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: